🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The LDL Cumulative Exposure Hypothesis The longer your arteries are exposed to high LDL-C, the ⬆️ the risk of atherosclerosis. 📈 🔬 Early & sustained LDL lowering = lifelong CV benefit. 🔗 nature.com/articles/s4156… #CardioTwitter #MedTwitter #FOAMed #MedED American College of Cardiology

8/Cantor’s pricing model for a one-time therapy falls in the range of 5x to 10x of the annual standard care cost. That means that $VERV-102 expected pricing range will be between ~$18,600 & ~$70,000 per dose. That means that even at the lowest target price - VERVE-102's projected

The PCSK9 gene is a key regulator of cholesterol in the liver. At Verve, we are developing VERVE-102, a single-course #geneediting medicine, designed to permanently turn off the PCSK9 gene in the liver to reduce blood LDL-C, (also known as the “bad cholesterol”) levels in people

Our team had a wonderful time at the #EASCongress2025 presenting recent highlights from our PCSK9 program and Verve’s vision of a one dose future to address #cardiovasculardisease. View the EAS presentation here: vervetx.com/sites/default/…

Honored, humbled and excited to become the inaugural Chair of Mass General Brigham Department of Medicine MassGeneral Medicine Brigham and Women's Hospital. Grateful to continue working with Bruce Levy and Colleen Curry in a unified Department as we navigate tumultuous waters ahead. AMCs have a future!

Whilst we wait for the results of the inclisiran CVOTs this analysis led by Benoit Arsenault using instrument variables to mimic hepatic and circulating pcsk9 suggests it’s all proportional to atherogenic lipid change #hope track.smtpsendmail.com/9032119/c?p=z3…

Congratulations to Kiran Musunuru and Team on this terrific work to create a bespoke adenine base editor to help a baby. Remarkable story of translation of science to clinical impact. I am particularly proud as Kiran was the first research trainee (post-doctoral fellow) in my

Dad and Mom (Penn '92) Dad and Daughter (Penn '25) Congratulations Nina Kathiresan! So proud of you and super excited for your path ahead.

"Genetic therapy is frankly a game changer," said Nissen. Instead of a lifetime of statins and PCSK9 treatments for a young person with inherited high cholesterol, a one-and-done DNA edit could knock out the troublesome gene altogether. Verve Therapeutics $VERV barrons.com/articles/strok…

So exciting when different agents from different companies each targeting same new pathway all lead to consistent clinical results APRIL protein as a target, IgA nephropathy as an indication, proteinuria reduction as outcome

We're excited to announce that Claire Mazumdar has been appointed to our Board of Directors. As CEO of Bicara Therapeutics, Claire's expertise and perspective as the leader of a late-stage clinical biotech will complement our board well. Welcome, Claire!

Happy Father’s Day to all the Dads Sure am proud of my crew! Cc: Nina Kathiresan

Today, we are thrilled to announce that Verve Therapeutics has entered into a definitive agreement to be acquired by Eli Lilly and Company From 2018 to 2025, Verve moved a new concept (a one-dose future for the treatment of atherosclerotic cardiovascular disease) and a new medical technology (in